222. Primary nephrotic syndrome Clinical trials / Disease details
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00801463 (ClinicalTrials.gov) | January 2009 | 2/12/2008 | Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis | Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis | Proteinuria;Focal Segmental Glomerulosclerosis | Drug: tripterygium wilfordii (TW) | Nanjing University School of Medicine | NULL | Completed | 18 Years | 60 Years | Both | 67 | N/A | China |
| 2 | NCT00518219 (ClinicalTrials.gov) | July 2007 | 16/8/2007 | To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) | To Compare the Efficacy and Safety of TW vs Valsartan in the MN | Membranous Nephropathy | Drug: TW | Nanjing University School of Medicine | NULL | Completed | 18 Years | 65 Years | Both | 68 | Phase 4 | China |